✦ LIBER ✦

PAO2: A COST-COST STUDY COMPARING ETANERCEPT WITH INFLIXIMAB IN MODERATE TO SEVERE RHEUMATOID ARTHRITIS

✍ Scribed by MJC Nuijten; PM Engelfriet; KJ Duijn; D Wierz; M Koopmanschap

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of adalimumab, etaner

✍ Soini, E. J.; Hallinen, T. A.; Puolakka, K.; Vihervaara, V.; Kauppi, M. J. 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 418 KB

PAO4: THE COST-EFFECTIVENESS OF CELECOXI

✍ E Orlewska 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

Cost effectiveness of adalimumab in the

✍ Bansback, N J 📂 Article 📅 2005 🏛 BMJ Publishing Group 🌐 English ⚖ 150 KB

Cost-effectiveness of abatacept in patie

✍ Vera-Llonch, M.; Massarotti, E.; Wolfe, F.; Shadick, N.; Westhovens, R.; Sofrygi 📂 Article 📅 2007 🏛 Oxford University Press 🌐 English ⚖ 134 KB

Indirect cost-effectiveness analyses of

✍ Yuan, Yong; Trivedi, Digisha; Maclean, Ross; Rosenblatt, Lisa 📂 Article 📅 2009 🏛 Informa plc 🌐 English ⚖ 488 KB

PAR 15 A COMPARISON OF COST OF INFLIXIMA

✍ S De Portu; G Ferraccioli; P Sarzi-Purrini; U Fiocco; C Montecucco; A Valesini; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB